Traded Feb 9 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Traded Jan 15, 2026 · Filed Jan 16, 2026
United Therapeutics's & GENERAL COUNSEL sold $192K of United Therapeutics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$192,219
Shares × reported transaction price
78 days after results of Oct 29, 2025, 41 days before results of Feb 25, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
Traded Feb 9 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.
Michael Benkowitz (PRESIDENT AND COO) sold ~$6.94M of United Therapeutics
Scheduled in advanceTraded Feb 9 · filed 2 days later
Derivative exercise or conversion — not an open-market buy.